SWOG clinical trial number
SWOG-8294 (INT-0011) (EST-1180)

Evaluation of Adjuvant Therapy and Biological Parameters in Node Negative Operable Female Breast Cancer

Closed
Phase
Published
Abbreviated Title
Evaluation of Adjuvant Therapy and Biological Parameters in Node Negative Operable Female Breast Cancer
Activated
05/15/1986
Closed
05/15/1988

Publication Information Expand/Collapse

1995

Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer.

RM Elledge;R Gray;E Mansour;Y Yu;P Ravdin;CK Osborne;K Gilchrist;NE Davidson;N Robert;DC Tormey;DC Allred Journal of the National Cancer Institute 87(16):1254-1256

1992

Prognostic significance of S-Phase fraction in good risk node-negative breast cancer patients.

MC Mathieu;MA Owens;LG Dressler;LE Eudey;DC Tormey;CK Osborne;KW Gilchrist;EG Mansour;MD Abeloff;WL McGuire JCO 10(3):428-432

Chemotherapy versus observation in high-risk node-negative breast cancer patients.

EG Mansour;L Eudey;DC Tormey;AH Shatila;CK Osborne;KW Gilchrist;MR Cooper;G Falkson Journal of the National Cancer Institute Monographs 11:97-104

1990

Adjuvant therapy in node-negative breast cancer. It is necessary for all patients. An Intergroup study.

EG Mansour;L Eudey;AH Shatila;DC Tormey;CK Osborne;KW Gilchrist;MR Cooper;R Gray;G Falkson Adjuvant Therapy of Cancer 6:174-189